Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial
Tajdini M, Aminorroaya A, Tavolinejad H, Tofighi S, Jalali A, Sadeghian S, Vasheghani-Farahani A, Yadangi S, Shahmansouri N, Akhondzadeh S, Bozorgi A. Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial. IJC Heart & Vasculature 2021, 34: 100789. PMID: 34027030, PMCID: PMC8129927, DOI: 10.1016/j.ijcha.2021.100789.Peer-Reviewed Original ResearchPre-syncopal episodesRecurrent vasovagal syncopeVasovagal syncopeEffects of atomoxetinePrimary endpointPlacebo groupMedian timeSubgroup analysis of patientsPre-syncopal attackNorepinephrine reuptake inhibitionPlacebo-controlled trialAnalysis of patientsPharmacological treatment optionsSystolic blood pressureDiagnosed VVSSyncope/pre-syncopeReduced quality of lifeReuptake inhibitionRandomized patientsAtomoxetine groupSyncopal episodesVasovagal attackTreatment optionsSubgroup analysisRandomized trials